Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
World game at war: why some European nations have threatened a World Cup boycott 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
CAMBRIDGE, Mass., May 08, 2018 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018, at 8 a.m. PT (11:00 a.m. ET) in Las Vegas, Nevada.
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts
Media:
Cristi Barnett
(617) 401-0113
[email protected]
Investors:
Mark Mullikin
(617) 401-9083
[email protected]
